Rutika J. Mehta, MD, MPH, a medical oncologist specializing in gastrointestinal cancer at Moffitt Cancer Center, discusses the role of biomarkers in gastric cancer.

Biomarkers such as microsatellite instability, mismatch repair ​deficiency, HER2 status, PD-L1 ​status, and tumor mutational burden are of interest in the gastric cancer space, says Mehta.

​Moreover, according to Mehta, all patients ​with metastatic disease should be ​molecularly profiled. 

​Additionally, if tissue is available, ordering next​-generation sequencing may be beneficial ​in terms of treatment selection and identifying available clinical trials, Mehta concludes. 

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Mehta on the Role of Biomarkers in Gastric Cancer